use
antibodi
amelior
advers
clinic
effect
microbi
infect
trace
back
late
centuri
work
von
behr
kitasato
serum
therapi
diphtheria
tetanu
review
ref
set
antibodi
act
neutral
bacteri
toxin
therapi
follow
serum
antibodi
target
directli
bacteri
viral
pathogen
viral
pathogen
enrich
polyclon
igg
molecul
immun
anim
shown
effect
prophylaxi
even
prophylaxi
exposur
number
virus
includ
hepat
viru
hepat
b
viru
hepat
c
viru
herp
simplex
viru
measl
viru
rabi
viru
respiratori
syncyti
viru
rsv
smallpox
viru
varicella
zoster
viru
gener
effect
antibodi
prepar
declin
durat
infect
often
regard
poor
therapeut
option
cours
major
antivir
strategi
centuri
vaccin
latter
part
earli
part
centuri
major
develop
understand
antibodi
abil
manipul
advent
hybridoma
technolog
provid
reliabl
sourc
mous
monoclon
antibodi
mab
first
impact
antibodi
therapi
character
cell
definit
cell
surfac
marker
broad
implement
mab
therapi
wait
develop
human
mous
antibodi
gener
fulli
human
antibodi
variou
techniqu
describ
antibodi
larg
appli
field
oncolog
autoimmun
singl
antivir
mab
rsvspecif
antibodi
palivizumab
widespread
clinic
use
reason
discuss
although
perhap
import
reason
fairli
high
cost
product
mab
difficulti
administr
belief
antibodi
larg
effect
prophylact
set
achiev
mani
virus
vaccin
howev
discuss
increas
number
antivir
antibodi
quit
remark
properti
term
potenc
andor
cross
reactiv
virus
strain
viru
isol
socal
superantibodi
chang
understand
hope
achiev
antibodi
microbi
infect
clinic
increas
potenc
greatli
reduc
unit
cost
treatment
make
altern
rout
administr
feasibl
extend
effect
halflif
antibodi
increas
cross
reactiv
allow
us
consid
target
multipl
virus
singl
antibodi
antibodi
engin
impact
potenc
cross
reactiv
greatli
extend
halflif
superantibodi
review
discuss
new
approach
fuell
identif
superantibodi
antibodi
may
best
appli
futur
direct
field
mani
acut
viral
infect
induc
robust
neutral
antibodi
respons
larg
major
individu
gener
virus
show
littl
evid
evas
antibodi
respons
refer
evas
lite
typic
either
display
limit
antigen
variabl
surfac
protein
protein
show
consider
variabl
nevertheless
express
immunodomin
conserv
epitop
exampl
virus
categori
includ
measl
viru
polioviru
chikungunya
viru
life
cycl
virus
presum
dictat
immun
evas
type
virus
isol
superantibodi
immun
donor
achiev
fairli
straightforward
howev
virus
evolv
mechan
evad
effect
neutral
antibodi
respons
term
evas
strong
virus
induc
respons
much
lower
level
effect
respons
context
infect
highli
antigen
variabl
virus
refer
neutral
potenc
also
effect
divers
circul
global
isol
often
refer
breadth
virus
includ
hiv
influenza
viru
ebola
viru
lassa
viru
proport
infect
individu
sometim
quit
small
gener
broad
potent
neutral
antibodi
furthermor
within
individu
potent
broadli
neutral
antibodi
bnab
specif
gener
constitut
small
fraction
antigenspecif
memori
b
cell
pool
exampl
small
percentag
hivinfect
individu
develop
broad
potent
serum
respons
time
b
cell
clone
effort
demonstr
bnab
gener
compris
hiv
envelop
env
specif
memori
b
cell
although
probabl
multipl
factor
contribut
low
abund
bnab
within
individu
intrins
natur
viral
env
protein
like
key
role
hiv
env
protein
evolv
multitud
mechan
evad
bnab
respons
includ
decoy
form
env
enorm
antigen
variabl
evolv
glycan
shield
immunodomin
variabl
epitop
poorli
access
conserv
furthermor
hivspecif
bnab
incorpor
unusu
featur
epitop
recognit
uncommonli
long
short
complementar
determin
region
loop
insert
delet
tyrosin
sulfat
extens
somat
hypermut
like
also
contribut
rariti
delay
develop
bnab
natur
case
influenza
viru
infect
vast
major
neutral
antibodi
elicit
infect
vaccin
bind
variabl
epitop
within
haemagglutinin
ha
globular
head
viral
particl
display
strainspecif
neutral
influenza
virusspecif
bnab
typic
target
conserv
ha
stem
region
variabl
rel
low
frequenc
bnab
ha
stem
perhap
due
typic
tight
pack
ha
trimer
viru
surfac
may
limit
antibodi
access
region
ebola
lassa
virus
extens
glycosyl
surfac
env
protein
result
mask
conserv
neutral
case
superantibodi
present
low
frequenc
within
immun
repertoir
largescal
donor
screen
highthroughput
b
cell
isol
platform
prove
critic
discoveri
superantibodi
past
sever
year
technolog
advanc
two
area
led
identif
larg
number
superantibodi
mostli
infect
individu
plethora
viral
pathogen
largescal
donor
screen
case
hiv
serv
prototyp
viru
mani
studi
systemat
select
donor
broadli
neutral
serum
respons
prove
critic
identif
superantibodi
hiv
field
oper
hand
bnab
limit
either
breadth
number
factor
complic
identif
bnab
includ
ineffici
tradit
approach
mab
discoveri
small
fraction
b
cell
secret
bnab
limit
avail
sampl
donor
develop
broad
potent
neutral
serum
respons
begin
problem
limit
sampl
address
establish
donor
screen
programm
identifi
hivinfect
individu
broadli
neutral
serum
respons
serv
sourc
materi
gener
one
largest
studi
hivinfect
individu
australia
rwanda
uganda
unit
kingdom
zambia
screen
broadli
neutral
sera
use
reduc
pseudoviru
panel
repres
global
circul
hiv
subset
individu
term
elit
neutral
identifi
exhibit
except
broad
potent
neutral
serum
respons
therefor
priorit
bnab
isol
past
year
mine
similar
sampl
led
identif
dozen
remark
broad
potent
hiv
care
select
donor
desir
serum
profil
also
enabl
isol
rare
superantibodi
influenza
viru
rsv
human
metapneumoviru
hmpv
rabi
viru
zika
exampl
paninfluenza
virusneutr
mab
rsv
hmpv
crossneutr
mab
isol
donor
select
basi
strong
heterotyp
serum
similarli
two
panlyssavirusneutr
mab
call
isol
memori
b
cell
four
donor
exhibit
potent
serumneutr
activ
multipl
lyssaviru
highthroughput
human
b
cell
isol
technolog
human
antivir
neutral
mab
isol
use
variou
differ
technolog
includ
combinatori
display
librari
human
immunoglobulin
transgen
mice
singl
b
cell
isol
method
fig
although
technolog
prove
valuabl
mab
gener
recent
burst
superantibodi
discoveri
primarili
driven
advanc
singl
b
cellbas
method
sever
possibl
reason
includ
ineffici
combinatori
librari
gener
interrog
lead
loss
rare
clone
alter
bind
characterist
antibodi
fragment
produc
heterolog
express
system
exampl
escherichia
coli
yeast
constraint
gener
suitabl
recombin
antigen
immun
librari
select
loss
nativ
heavychain
lightchain
pair
immun
librari
gener
inher
differ
adapt
immun
system
human
mice
sever
technolog
breakthrough
b
cell
clone
arena
critic
fuell
superantibodi
identif
one
advanc
came
direct
function
screen
thousand
b
cell
clone
hiv
elit
neutral
led
isol
two
superantibodi
approxim
order
magnitud
potent
firstgener
notabl
bind
poorli
recombin
env
protein
thu
would
identifi
without
direct
function
screen
b
cell
supernat
date
mani
dozen
hivspecif
bnab
target
divers
rang
epitop
identifi
use
function
screen
highli
potent
superantibodi
rsv
hmpv
lassa
viru
human
cytomegaloviru
hcmv
also
discov
use
highthroughput
function
screen
tabl
similar
superantibodi
isol
screen
b
cell
supernat
basi
capac
neutral
infect
vitro
subsequ
found
react
poorli
current
avail
recombin
env
protein
case
rsv
approach
led
isol
highli
potent
mab
bind
epitop
exclus
express
prefus
conform
rsv
fusion
glycoprotein
f
protein
engin
variant
mab
exhibit
time
greater
neutral
potenc
palivizumab
test
clinic
trial
prevent
rsvassoci
diseas
highrisk
infant
second
rsv
prefus
f
proteinspecif
superantibodi
crossneutr
sever
differ
paramyxovirus
includ
hmpv
also
isol
screen
b
cell
supernat
neutral
tabl
case
hcmv
direct
function
screen
enabl
isol
highli
potent
superantibodi
specif
conform
epitop
within
pentam
complex
previous
known
target
neutral
direct
function
screen
approach
also
led
discoveri
potent
superantibodi
middl
east
respiratori
syndrom
coronaviru
merscov
ebola
viru
influenza
viru
chikungunya
viru
rabi
viru
poxviru
notabl
case
merscov
b
cell
cultur
screen
show
neutral
similarli
paninfluenza
virusneutr
mab
isol
test
plasma
cell
eight
immun
final
mab
select
basi
abil
neutral
rabi
viru
show
crossneutr
activ
multipl
lyssaviru
exampl
clearli
illustr
exhaust
interrog
immun
repertoir
often
requir
identif
rare
crossneutr
superantibodi
second
breakthrough
hiv
antibodi
field
follow
develop
technolog
antigenspecif
singl
b
cell
approach
coupl
use
ration
design
env
probe
allow
discoveri
two
new
potent
hivspecif
bnab
target
conserv
bind
tabl
follow
discoveri
sever
potent
bnab
bind
site
isol
use
similar
recent
advanc
gener
recombin
nativelik
hiv
env
trimer
enabl
identif
except
potent
mani
hiv
superantibodi
gener
use
singl
b
cell
sort
use
fluoresc
label
probe
sort
antigenspecif
memori
b
cell
also
enabl
discoveri
highli
potent
superantibodi
ebola
viru
rsv
human
papilloma
viru
hpv
zika
viru
influenza
case
ebola
viru
largescal
singl
b
cell
clone
effort
led
isol
sever
hundr
mab
specif
ebola
viru
envelop
glycoprotein
gp
two
show
potent
panebola
virusneutr
activ
protect
similar
effort
rsv
field
allow
isol
sever
prefus
fproteinspecif
mab
show
time
potent
neutral
activ
addit
multipl
group
use
clever
dualantigen
label
strategi
identifi
potent
bnab
hiv
influenza
viru
ebola
viru
structur
sever
superantibodi
bound
viral
target
shown
figur
final
recent
report
show
bnab
hiv
readili
elicit
cow
use
singl
env
trimer
immunogen
induct
depend
long
heavychain
loop
bovin
immunoglobulin
possibl
repertoir
may
provid
advantag
gener
superantibodi
pathogen
vaccin
infectioninduc
antibodysecret
cell
asc
respons
also
prove
rich
sourc
antigenspecif
antibodi
follow
earli
studi
show
transient
larg
popul
asc
appear
peripher
blood
day
tetanu
toxoid
booster
shown
influenza
viru
vaccin
produc
similar
asc
respons
larg
major
mab
clone
cell
bound
high
affin
influenza
viru
provid
proof
concept
asc
respons
could
exploit
rapidli
gener
antigenspecif
antibodi
immun
date
plasmablast
clone
led
isol
mab
mani
differ
virus
includ
dengu
viru
zika
viru
hiv
influenza
viru
vaccinia
viru
one
advantag
plasmablast
approach
antigen
bait
requir
b
cell
sort
therebi
allow
isol
antibodi
target
epitop
poorli
present
recombin
antigen
exampl
case
dengu
viru
potent
bnab
target
edimerdepend
epitop
isol
use
howev
import
emphas
abil
isol
superantibodi
use
method
depend
sever
factor
first
primari
infect
asc
popul
mainli
compos
activ
lowaffin
naiv
b
cell
rather
affinitymatur
memori
b
cell
make
possibl
identifi
superantibodi
extrem
unlik
second
context
booster
vaccin
secondari
infect
antigen
similar
viru
plasmablast
respons
direct
immunodomin
epitop
mani
case
target
effect
neutral
antibodi
case
exhaust
clone
product
character
plasmablastderiv
mab
would
like
requir
identifi
rare
superantibodi
contrast
secondari
infect
antigen
relat
suffici
diverg
viru
drive
preferenti
expans
b
cell
target
highli
conserv
epitop
exemplifi
unusu
high
frequenc
bnab
induc
donor
infect
novel
influenza
viru
ref
principl
one
could
use
type
approach
gener
superantibodi
human
mice
anim
model
use
suitabl
design
immunogen
immun
regimen
past
two
decad
human
face
newli
emerg
reemerg
viral
threat
almost
everi
year
includ
sever
acut
respiratori
syndrom
coronaviru
sar
west
nile
viru
pandem
influenza
viru
ebola
viru
merscov
zika
viru
compar
fast
path
approv
gener
favour
safeti
profil
mab
therapi
repres
promis
altern
vaccin
smallmolecul
drug
treatment
prevent
emerg
viral
threat
recent
sever
laboratori
demonstr
feasibl
identifi
character
scalingup
product
highli
potent
mab
remark
short
time
frame
respons
merscov
outbreak
two
differ
group
illustr
power
mab
discoveri
platform
isol
highli
potent
mersspecif
mab
produc
mab
gram
quantiti
test
lead
mab
anim
model
unpreced
one
studi
singl
highli
potent
merscovneutr
mab
identifi
memori
b
cell
convalesc
donor
use
highthroughput
function
screen
mab
call
show
protect
exposur
mous
model
merscov
infect
importantli
process
took
author
month
initi
b
cell
screen
develop
stabl
cell
line
produc
neutral
mab
g
second
studi
human
immunoglobulin
transgen
mice
immun
merscov
spike
protein
use
gener
panel
potent
merscovspecif
neutral
mab
within
sever
author
also
quickli
gener
human
mous
model
merscov
infect
use
demonstr
therapeut
efficaci
mab
third
studi
vaccin
transchromosom
cow
engin
produc
fulli
human
igg
molecul
merscov
shown
yield
high
serum
titr
merscovspecif
neutral
importantli
administr
purifi
polyclon
transchromosom
bovin
human
igg
mice
either
hour
hour
merscov
infect
result
signific
reduct
viral
lung
titr
transchromosom
bovin
also
use
rapidli
gener
polyclon
neutral
antibodi
hanta
viru
venezuelan
equin
enceph
viru
ebola
demonstr
feasibl
use
platform
rapidli
gener
therapeut
combat
emerg
viral
threat
antibodi
aris
transchromosom
cow
polyclon
date
potenti
mab
isol
sever
group
respond
ebola
viru
outbreak
swiftli
gener
highli
potent
ebola
viru
gpspecif
neutral
mab
memori
b
cell
convalesc
mani
mab
show
potent
therapeut
efficaci
either
ebola
bundibugyo
viru
exposur
anim
model
subset
show
protect
efficaci
multipl
ebola
viru
similarli
sever
group
recent
report
isol
potent
zikavirusspecif
neutral
mab
human
notabl
one
neutral
mab
call
show
protect
zika
viru
exposur
pregnant
nonpregn
certain
case
avail
superantibodi
target
highli
conserv
epitop
may
shorten
timelin
bypass
need
mab
discoveri
exampl
recent
shown
subset
denguevirusspecif
mab
potent
crossneutr
zika
bnab
perhap
carri
fc
mutat
ablat
fc
receptor
bind
avoid
potenti
antibodydepend
could
immedi
use
prophylaxi
pregnant
women
live
zikavirusendem
region
notabl
cocktail
superantibodi
target
differ
epitop
bispecif
trispecif
superantibodi
construct
like
requir
prevent
neutral
antibodi
function
virus
sever
mechan
primarili
divid
activ
free
viru
particl
activ
infect
cell
neutral
measur
vitro
abil
antibodi
prevent
viral
entri
target
cell
without
requir
involv
agent
activ
free
virion
correl
protect
vivo
activ
infect
cell
gener
depend
fc
effector
function
involv
host
effector
cell
includ
antibodydepend
cellular
cytotox
adcc
complementdepend
cytotox
antibodydepend
cellular
phagocytosi
adcp
presum
activ
like
import
antibodybas
therapi
neutral
frequent
correl
abil
bind
nativ
structur
virion
surfac
give
indic
abil
antibodi
mediat
effector
activ
adcc
adcp
potenc
superantibodi
often
estim
neutral
measur
although
ultim
cours
vivo
activ
crucial
prophylaxi
vaccin
effect
lowcost
method
prevent
viral
diseas
howev
develop
effect
vaccin
mani
import
viral
pathogen
includ
hiv
rsv
hepat
c
viru
dengu
viru
hcmv
met
limit
success
furthermor
vaccin
develop
long
complex
process
often
last
year
make
immun
impract
mean
protect
individu
newli
emerg
viral
threat
unless
panviru
famili
vaccin
develop
exampl
antibodi
identifi
potent
neutral
exist
strain
ebola
viru
even
ebola
marburg
filovirus
one
could
anticip
vaccin
templat
antibodi
would
also
effect
emerg
strain
ebola
viru
howev
current
time
passiv
antibodi
prophylaxi
repres
promis
altern
vaccin
number
viral
infect
current
three
purifi
polyclon
hyperimmun
globulin
deriv
human
donor
immun
hepat
b
viru
hcmv
varicella
zoster
viru
market
prevent
seriou
diseas
associ
virus
rabiesvirusspecif
immun
globulin
combin
vaccin
also
avail
prophylaxi
exposur
palivizumab
human
mab
target
rsv
f
protein
becam
first
antivir
mab
approv
us
food
drug
administr
palivizumab
soon
replac
rsv
hyperimmun
globulin
respigam
prevent
sever
rsvassoci
diseas
highrisk
infant
howev
although
palivizumab
specif
time
potent
respigam
cost
associ
requir
dose
make
use
impract
secondgener
rsvspecif
mab
show
time
greater
neutral
potenc
palivizumab
contain
substitut
fc
domain
extend
serum
halflif
current
phase
ii
clinic
trial
prevent
sever
rsvassoci
diseas
tabl
although
palivizumab
commerci
avail
mab
prevent
viral
diseas
multipl
antivir
mab
preclin
clinic
develop
shown
efficaci
prior
exposur
anim
model
exampl
potent
merscovspecif
mab
describ
shown
prophylact
protect
human
mice
mersassoci
diseas
similarli
mab
chikungunya
viru
influenza
viru
hiv
ebola
viru
shown
potent
prophylact
efficaci
anim
recent
broadli
neutral
antizika
viru
mab
shown
protect
transmiss
mous
model
zika
viru
observ
translat
human
prophylaxi
similar
neutral
mab
may
promis
mean
protect
atrisk
pregnant
women
zika
viru
infect
fetal
transmiss
case
hiv
multipl
studi
shown
passiv
administ
neutral
mab
provid
protect
intraven
vagin
rectal
oral
challeng
nonhuman
primat
mous
larg
ongo
studi
antibodymedi
prevent
amp
studi
assess
abil
mab
specif
bind
site
decreas
risk
hiv
acquisit
human
although
anim
studi
provid
proof
principl
vaccin
capabl
induc
suffici
titr
bnab
could
prevent
establish
hiv
infect
human
amp
studi
investig
directli
design
immunogen
effici
elicit
rare
antibodi
remain
formid
challeng
bypass
challeng
associ
activ
vaccin
hiv
number
group
propos
altern
strategi
basi
vectormedi
antibodi
gene
transfer
express
bnab
unlik
tradit
passiv
immun
would
requir
longterm
repeat
treatment
bnab
vector
immunoprophylaxi
involv
singl
inject
enabl
continu
sustain
deliveri
antibodi
pioneer
work
demonstr
vectormedi
deliveri
antibodylik
molecul
provid
vaccinelik
protect
simian
immunodefici
viru
siv
challeng
nonhuman
primat
subsequ
studi
shown
vector
immunoprophylaxi
also
compat
fulllength
igg
molecul
preclin
result
mice
macaqu
translat
human
vector
antibodi
gene
deliveri
strategi
could
provid
altern
form
prophylaxi
hiv
challeng
vaccin
target
hepat
c
viru
pandem
influenza
viru
malaria
recent
nonvir
vector
nucleic
acid
deliveri
technolog
also
develop
obviat
potenti
safeti
issu
associ
viral
vectormedi
deliveri
longterm
persist
potenti
viral
dna
integr
host
recent
studi
shown
administr
lipidencapsul
nucleosidemodifi
mrna
encod
heavychain
lightchain
gene
broadli
neutral
antibodi
human
mice
result
high
serum
antibodi
concentr
protect
intraven
similar
proofofconcept
studi
also
perform
use
synthet
dna
plasmidmedi
antibodi
gene
one
studi
synthet
dna
plasmid
encod
crossneutr
antidengu
viru
antibodi
deliv
mice
electropor
result
biolog
relev
level
serum
importantli
singl
intramuscular
inject
plasmid
dna
confer
protect
sever
dengu
diseas
mous
model
although
sever
technic
challeng
remain
address
enhanc
vivo
antibodi
express
level
reduc
potenti
immunogen
studi
demonstr
feasibl
util
plasmid
dna
modifi
mrnabas
antibodi
deliveri
technolog
passiv
immunotherapi
therapi
convent
wisdom
say
antibodi
effect
present
shortli
viral
exposur
effect
declin
markedli
infect
establish
exampl
antirsv
antibodi
palivizumab
effect
clinic
prophylact
howev
indic
dogma
may
challeng
superantibodi
exampl
abil
new
gener
bnab
hiv
strongli
impact
ongo
infect
anim
earlier
gener
lesspot
mab
limit
abil
like
reflect
increas
neutral
potenc
superantibodi
well
increas
breadth
neutral
may
restrict
viru
escap
number
superantibodi
evalu
human
activ
establish
hiv
tabl
initi
result
interest
provid
exampl
indic
enhanc
immun
respons
follow
bnab
emerg
result
follow
close
includ
context
combin
bnab
drug
antivir
agent
attempt
hiv
cure
virus
clear
evid
strong
therapeut
effect
superantibodi
gather
yet
sever
case
antibodi
treatment
rabi
viru
junin
viru
probabl
better
interpret
prophylaxi
exposur
rather
therapi
establish
infect
two
promis
exampl
possibl
therapi
success
treatment
ebolavirusinfect
lassavirusinfect
monkey
mab
symptom
unfortun
definit
evid
effect
mab
ebolasymptomat
lassasymptomat
human
yet
exist
camelidderiv
singledomain
antibodi
sdab
contain
singl
heavychain
variabl
domain
repres
promis
new
class
antibodybas
therapeut
rsv
virus
caus
lower
respiratori
tract
small
size
high
solubl
stabil
sdab
rapidli
deliv
site
infect
via
inhal
notabl
neutral
antirsv
sdab
target
epitop
overlap
bound
palivizumab
recent
show
trend
toward
therapeut
effect
phase
iia
clinic
trial
base
reduc
viral
load
clinic
symptom
hospit
rsvinfect
infant
prefus
fproteinspecif
sdab
show
time
greater
neutral
potenc
recent
identifi
may
offer
even
greater
therapeut
intuit
enhanc
potenc
superantibodi
immedi
recogn
benefici
antibodi
prophylaxi
therapi
howev
also
number
addit
effect
enhanc
potenc
may
instantli
appreci
strengthen
antibodi
engin
exampl
enhanc
potenc
mean
less
antibodi
need
use
enabl
easiertodevelop
lowconcentr
subcutan
administr
rather
use
moredifficulttodevelop
highconcentr
subcutan
administ
formul
lessconveni
lowconcentr
intraven
administr
enhanc
potenc
also
mean
lifetim
effect
antibodi
follow
administr
extend
therebi
requir
fewer
administr
maintain
use
protect
therapeut
effect
antibodi
engin
also
extend
halflif
potent
superantibodi
one
could
envisag
requir
administr
perhap
everi
month
effect
antibodi
engin
also
deliv
greater
effect
enhanc
fc
effector
deploy
antibodi
antivir
agent
progress
number
stage
year
correspond
increas
level
potenc
reagent
administ
passiv
immunotherapi
began
immun
serum
centuri
ago
progress
polyclon
antibodi
mab
highli
potent
human
mab
dub
superantibodi
thank
research
primarili
carri
field
cancer
research
technolog
develop
endow
superantibodi
enhanc
vivo
function
superantibodi
chang
landscap
antivir
prophylaxi
therapi
answer
question
depend
number
factor
first
rapid
develop
antivir
vaccin
vaccin
like
remain
least
expens
effect
antivir
measur
virus
hiv
present
larg
challeng
vaccin
develop
second
effect
cost
antibodi
treatment
incorpor
manufactur
cost
also
durabl
administ
antibodi
rout
administr
third
success
antibodi
treatment
establish
viral
infect
particularli
therapeut
set
answer
obtain
clinic
trial
use
best
superantibodi
avail
springer
natur
remain
neutral
regard
jurisdict
claim
publish
map
institut
affili
natur
review
immunolog
thank
jame
crow
jr
antonio
lanzavecchia
gavin
screaton
contribut
peer
review
work
